Clinical Trial Update: A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study evaluating the safety and tolerability of GSK3996401 after dosing with GSK4347859 in healthy participants has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GSK3996401
• GSK4347859

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: SUSPENDED